


Anti-Diastereoselective Synthesis of CF_3 -Containing Spirooxazolines and Spirooxazines via Regiospecific Trifluoromethylative Spirocyclization by Photoredox Catalysis

Naoki Noto, Kazuki Miyazawa, Takashi Koike,* and Munetaka Akita*

Chemical Resources Laboratory, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama 226-8503, Japan

Supporting Information

ABSTRACT: A novel synthesis of CF_3 -containing spirooxazolines and spirooxazines has been developed. Regiospecific trifluoromethylative spirocyclization (CF_3 -spirocyclization) of cyclic alkenes bearing an amide pendant mediated by photoredox catalysis is a useful strategy for construction of a $\text{C}(\text{sp}^3)\text{—CF}_3$ bond and an spirooxazoline or spirooxazine ring onto $\text{C}=\text{C}$ bonds via a single step. The key intermediate is $\alpha\text{-CF}_3$ -substituted carbocationic species smoothly generated from single-electron-transfer (SET) photoredox processes, which results in diastereoselective spirocyclization. This is the first example of synthesis of CF_3 -containing spirooxazolines and spirooxazines in *anti*-fashion with respect to the CF_3 group and the oxygen atom of the spirocycles.




Spirooxazoline and spirooxazine scaffolds are useful structural motifs in many biologically active molecules.¹ Thus, development of synthetic methodologies for their derivatives has attracted great interest from synthetic chemists for years.

One of the most useful strategies for synthesis of functionalized spirooxazoline and spirooxazine is regioselective cyclization of cyclic alkenes with an amide pendant induced by electrophilic activation of the olefinic moiety. Another good aspect for the reaction of internal alkenes is an opportunity for the construction of two stereogenic centers via a single step. While synthesis of oxazolines and oxazines through cyclization of allylic amides triggered by strongly electrophilic reagents such as halogen and selenium electrophiles has been well-documented so far (Scheme 1a),^{2–4} application of this strategy to the

synthesis of spirooxazolines and spirooxazines has been limited.⁵ In 2011, the group of Toste reported that anion-based chiral phase transfer catalyst (PTC) induced asymmetric fluorospirocyclization of allylic amides, leading to fluorinated spirooxazolines (the upper process in Scheme 1b).^{5d} But useful synthetic protocols for spiro-fused rings through cyclization accompanied by functionalization, especially carbo-spirocyclization, are still rare.⁴

The trifluoromethyl group (CF_3) is widespread in pharmaceutical and agrochemical fields because it influences chemical and metabolic stability, lipophilicity, and binding selectivity, resulting in unique bioactive properties.^{6,7} Recently, photoredox catalysis⁸ with ruthenium(II) polypyridine complexes (e.g., $[\text{Ru}(\text{bpy})_3]^{2+}$: bpy = 2,2'-bipyridine) and the relevant cyclometalated iridium(III) derivatives has been recognized as a powerful tool for radical trifluoromethylation.^{9,10} For the past few years, our group has been extensively developing photoredox-catalyzed trifluoromethylative difunctionalization of olefins.¹¹ Our protocol is featured by (i) the use of shelf-stable electrophilic trifluoromethylating reagents such as Umemoto's reagent **1**¹² as a trifluoromethyl radical source and (ii) regioselective generation of $\alpha\text{-CF}_3$ -substituted carbocationic intermediate from olefins through single-electron-transfer (SET) photoredox processes, which is rather difficult to generate by other methods. We expected that application of photoredox-catalyzed trifluoromethylation to cyclic alkenes bearing a nucleophilic amide moiety leads to CF_3 -containing spirooxazolines and spirooxazines through intramolecular nucleophilic attack of the oxygen atom in the amide functionality to an $\alpha\text{-CF}_3$ -substituted carbocationic intermediate.

Scheme 1. Synthesis of Heterocycles through Functionalization–Cyclization Sequence of Alkenes Bearing an Amide Pendant



Received: June 10, 2015



ACS Publications

© XXXX American Chemical Society

A

DOI: 10.1021/acs.orglett.5b01694
Org. Lett. XXXX, XXX, XXX–XXX

Herein we describe the regiospecific trifluoromethylative spirocyclization (CF_3 -spirocyclization) of cyclic alkenes bearing an amide pendant mediated by photoredox catalysis, i.e., photoredox-catalyzed oxytrifluoromethylation,^{4c,10e,l,11a,g} to be a versatile protocol for access to CF_3 -containing spirooxazolines and spirooxazines. In addition, this is the first report on predominant formation of *anti*-diastereomers of CF_3 -containing spirocyclic compounds.¹³


We initially examined the photocatalytic reaction of *N*-(*(3,4-dihydronaphthalen-1-yl)methyl*)benzamide (**2a**) with Umemoto's reagent **1** in the presence of 5 mol % $[\text{Ru}(\text{bpy})_3](\text{PF}_6)_2$ in acetone-*d*₆ at room temperature under visible light irradiation with blue LED lamps ($\lambda_{\text{max}} = 425 \pm 15 \text{ nm}$). After 1.5 h, **2a** was completely converted but the corresponding spirooxazoline **3a** was not formed at all (Table 1, entry 1). Instead, a *N*-protonated

Table 1. Optimization of the Photocatalytic CF_3 -Spirocyclization of Allylic Amide (2a**)^a**

entry	base	solvent	temp	% yield of 3a ^b	
				dr ^b	Yield
1	none	acetone- <i>d</i> ₆	rt	— ^c	—
2	K_2CO_3	acetone- <i>d</i> ₆	rt	— ^c	—
3	2,6-lutidine	acetone- <i>d</i> ₆	rt	91	77:23
4	2,6-lutidine	acetone- <i>d</i> ₆	−78 °C	91	84:16
5	2,6-lutidine	CD_2Cl_2	−78 °C	90	74:26
6 ^d	2,6-lutidine	acetone- <i>d</i> ₆	−78 °C	0	—
7 ^e	none	acetone- <i>d</i> ₆	−78 °C	0	—
8 ^e	2,6-lutidine	acetone- <i>d</i> ₆	−78 °C	28, 37 ^f	74:26 ^f

^aReaction conditions: A mixture of $[\text{Ru}(\text{bpy})_3](\text{PF}_6)_2$ (1.25 μmol , 5 mol %), **1** (28 μmol , 1.1 equiv), **2a** (25 μmol , 1.0 equiv), and solvent (0.4 mL) was irradiated by 3 W blue LEDs ($\lambda = 425 \pm 15 \text{ nm}$). ^bYields and diastereomer ratios (dr) were determined by ¹H NMR spectroscopy using SiEt₄ as an internal standard. ^cProtonated **3a** was formed. ^dIn the dark. ^eNo photocatalyst. ^fReaction time = 8 h.

Scheme 2. Scope of the Present Photocatalytic CF_3 -Spirocyclization of Allylic Amides (2**)^{a,b,c}**



^aReaction conditions: see the Supporting Information. ^bYields were obtained after purification. ^cDiastereomer ratios (dr) were determined by ¹H and ¹⁹F NMR spectra of crude reaction mixtures. ^d CH_2Cl_2 was used as a solvent due to solubility of substrate. ^eReaction was carried out in the presence of 1.7 equiv of **1** at 0 °C for 4 h.

compound type of **3a** was likely to be formed (see the Supporting Information). Therefore, addition of a base, K_2CO_3 and 2,6-lutidine, was tested. K_2CO_3 showed a result similar to entry 1 possibly due to its low solubility (entry 2). In contrast, to our delight, 2,6-lutidine yielded the product **3a** in a good yield (91%) with good diastereoselectivity (77:23 dr) (entry 3). Next, to improve the diastereoselectivity, the reaction was conducted at −78 °C (in a dry ice–methanol bath), resulting in better diastereoselectivity (84:16 dr) (entry 4). Use of CD_2Cl_2 as a solvent also afforded the product smoothly (90% yield) but with a slightly lower diastereoselectivity (74:26 dr) (entry 5). Finally, the reaction did not proceed at all either in the dark or in the absence of a photocatalyst (entries 6 and 7). To our surprise, 2,6-lutidine also promoted the reaction to some extent even in the absence of the photocatalyst (entries 7 and 8).¹⁴ But, even after a longer reaction time, the yield was much lower than that obtained by photoredox catalysis, suggesting that the reaction promoted by 2,6-lutidine is not the main reaction pathway of the present photocatalysis.

With the optimal reaction conditions in hand, the preparative scale experiments were performed. Then, we found that the catalyst loading can be reduced to 0.5 mol %. The obtained CF_3 -containing spirooxazolines **3** were summarized in Scheme 2.

First, substituents on the amide pendants were explored. Substrates with benzene rings bearing halogens, Br (**2b**) and I (**2c**), and an electron-donating group, MeO (**2d**), and aliphatic groups, Me (**2e**) and ^tBu (**2f**), afforded the corresponding spirooxazoline products (**3b–f**) in good to high yields (59–86%) with moderate to good diastereoselectivities (72:28–86:14 dr). Amide functionalities with an alkoxy group, OEt (**2g**), a trichloromethyl group (**2h**), a naphthyl group (**2i**), and a pyridyl group (**2j**) tolerated the present photocatalytic system (**3g–j**: 52–85%, 75:25–86:14 dr). Remarkably, the alkene with a bulky mesitylamide pendant (**2k**) gave **3k** in a 73% yield with excellent diastereoselectivity (97:3 dr). Next, structures of cyclic alkenes were investigated. Reactions of *N*-(*(2H*-benzopyran-4-yl)-methyl)benzamide (**2l**) and *N*-(*(2H*-thiocromen-4-yl)methyl)benzamide (**2m**) proceeded without any retardation regardless of the ether and sulfide functionalities to give the corresponding CF_3 -spirocyclized products in good yields (**3l**: 71%, 88:12 dr and **3m**: 64%, 89:11 dr) in a diastereoselective manner, respectively. The reaction of *N*-(*(1H*-inden-3-yl)methyl)benzamide (**2n**) also afforded a good yield of the CF_3 -containing spirooxazoline (**3n**: 77%) but with slightly lower diastereoselectivity (77:23 dr) compared to the dihydronaphthalenyl skeleton (**3a**). A tetrasubstituted alkene, ((*1H*-2-methyl-inden-3-yl)methyl)benzamide (**2o**)

benzamide (**2o**), could be also applied to the present reaction, leading to the CF₃-spirooxazoline with a quaternary carbon atom **3o** (46%) but virtually with no diastereoselectivity (52:48 dr). These results suggest that the present photocatalytic system is amenable to diastereoselective synthesis of CF₃-containing spirooxazolines from cyclic alkenes with various amide pendants. Diastereoselectivity is considerably dependent on the substituent of the amide group and the structure of the cyclic alkenes.

The stereochemistry of the major diastereomer of CF₃-spirooxazolines **3c** and **3n** was unequivocally confirmed by single-crystal X-ray analysis.¹⁵ An ORTEP drawing of the major diastereomer (*1R*^{*},*2S*^{*})-**3n** is depicted in Figure 1. These results revealed *anti*-stereochemistry for the nucleophilic cyclization process with respect to the CF₃ group.





Figure 1. An ORTEP drawing of the major diastereomer of CF₃-containing spirooxazoline (1*R*^{*},2*S*^{*})-**3n**. The thermal ellipsoids are set at a 50% probability level.

Extension to amides with longer tethers, *N*-(2-(3,4-dihydro-naphthalen-1-yl)ethyl)benzamides **4**, was further examined (Scheme 3). It was observed that the corresponding CF₃-

Scheme 3. Diastereoselective Synthesis of CF₃-Containing Spirooxazines




containing spirooxazines **5** were obtained in good yields (51–67% yield).¹⁵ It should be noted that diastereomer ratios of the products (**5a**, **5b**, **5d**) (89:11–91:9 dr) were substantially enhanced compared to the above-mentioned spirooxazolines with the five-membered rings (**3a**, **3b**, **3d**) with the same substituent on the amide pendant. Single-crystal X-ray analysis for the major diastereomer of **5b** revealed the present spirocyclization also proceeded in an *anti*-fashion (see the Supporting Information). These results show that the present reaction system serves as a facile synthetic method for both *anti*-CF₃-spirooxazolines and -spirooxazines from cyclic alkenes with amide tethers.

The reaction appears to proceed through a mechanism similar to that of the previously reported photocatalytic oxytrifluoromethylation^{11a} (for the full proposed mechanism, see the Supporting Information). SET photoredox processes mediated

by [Ru(bpy)₃]²⁺ for the reaction of Umemoto's reagent **1** with cyclic alkenes **2** or **4** generates an α -CF₃-substituted carbocationic intermediate regiospecifically. This key intermediate undergoes intramolecular nucleophilic attack of the dangling amide moiety in an *anti*-fashion presumably due to the steric factor of the CF₃ substituent. These regiospecific trifluoromethylation and *anti*-selective cyclization processes lead to the predominant formation of *anti*-diastereomers of CF₃-containing spirooxazolines **3** or spirooxazines **5** (Scheme 4).

Scheme 4. A Plausible Reaction Mechanism for Anti-Diastereoselectivity



In conclusion, we have developed a simple synthesis of both CF₃-containing spirooxazolines and spirooxazines from cyclic alkenes bearing an amide pendant through trifluoromethylative spirocyclization (CF₃-spirocyclization) mediated by photoredox catalysis under mild conditions. Regiospecific radical trifluoromethylation and *anti*-selective nucleophilic attack of the amide pendant to the α -CF₃-substituted carbocationic intermediate lead to the formation of CF₃-spirocycles in good to excellent diastereoselectivity. This is the first example of an access to *anti*-diastereomers of CF₃-containing spirooxazolines and spirooxazines. Further studies on stereoselective trifluoromethylation are underway in our laboratory.

ASSOCIATED CONTENT

S Supporting Information

Details of experimental procedures, control experiments and full spectroscopic data for all new compounds, crystallographic data for (1*R*^{*},2*S*^{*})-**3c** (CCDC 1049302), (1*R*^{*},2*S*^{*})-**3n** (CCDC 1049303), and (1*R*^{*},2*S*^{*})-**5b** (CCDC 1049304). The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01694.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: koike.t.ad@m.titech.ac.jp.

*E-mail: makita@res.titech.ac.jp.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by JSPS KAKENHI Grant Numbers (26288045 and 15K13689) and the Naito Foundation.

■ REFERENCES

- (1) (a) Harnden, M. R.; Rasmussen, R. R. *J. Med. Chem.* **1970**, *13*, 305. (b) Suchy, M.; Kutschy, P.; Monde, K.; Goto, H.; Harada, N.; Takasugi, M.; Dzurilla, M.; Balentová, E. *J. Org. Chem.* **2001**, *66*, 3940. (c) Nair, V.; Sethumadhavan, D.; Nair, S. M.; Viji, S.; Rath, N. P. *Tetrahedron* **2002**, *58*, 3003. (d) Breschi, M. C.; Calderone, V.; Digiocomo, M.; Manganaro, M.; Martelli, A.; Minutolo, F.; Rapposelli, S.; Testai, L.; Tonelli, F.; Balsamo, A. *J. Med. Chem.* **2008**, *51*, 6945. (e) Szakonyi, Z.; Hetényi, A.; Fülop, F. *ARKIVOC* **2007**, *2008*, 33. (f) Shih, H.-W.; Guo, C.-W.; Lo, K.-H.; Huang, M.-Y.; Cheng, W.-C. *J. Comb. Chem.* **2009**, *11*, 281. (g) Jiang, X.; Cao, Y.; Wang, Y.; Liu, L.; Shen, F.; Wang, R. *J. Am. Chem. Soc.* **2010**, *132*, 15328. (h) Zhou, H.; Topiol, S. W.; Grenon, M.; Jimenez, H. N.; Uberti, M. A.; Smith, D. G.; Brodbeck, R. M.; Chandrasena, G.; Pedersen, H.; Madsen, J. C.; Doller, D.; Li, G. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 1398.
- (2) For selected reviews, see: (a) Robin, S.; Rousseau. *Tetrahedron* **1998**, *54*, 13681. (b) Denmark, S. E.; Kuester, W. E.; Burk, M. T. *Angew. Chem., Int. Ed.* **2012**, *51*, 10938. (c) Hennecke, U. *Chem. - Asian J.* **2012**, *7*, 456. (d) Tripathi, C. B.; Mukherjee, S. *Synlett* **2014**, *25*, 163.
- (3) For selected examples of halo- and seleno-cyclization, see: (a) Goodman, L.; Winstein, S. *J. Am. Chem. Soc.* **1957**, *79*, 4788. (b) McManus, S. P.; Ware, D. W.; Hames, R. A. *J. Org. Chem.* **1978**, *43*, 4288. (c) Parker, K. A.; O'Fee, R. *J. Am. Chem. Soc.* **1983**, *105*, 654. (d) Cardillo, G.; Orena, M.; Sandri, S.; Tomasini, C. *Tetrahedron* **1985**, *41*, 163. (e) Commerçon, A.; Ponsinet, G. *Tetrahedron Lett.* **1990**, *31*, 3871. (f) Engman, L. *J. Org. Chem.* **1991**, *56*, 3425. (g) Galeazzi, R.; Martelli, G.; Mobbili, G.; Orena, M.; Rinaldi, S. *Org. Lett.* **2004**, *6*, 2571. (h) Minakata, S.; Morino, Y.; Oderoatoshi, Y.; Komatsu, M. *Org. Lett.* **2006**, *8*, 3335. (i) Jaganathan, A.; Garzan, A.; Whitehead, D. C.; Staples, R. J.; Borhan, B. *Angew. Chem., Int. Ed.* **2011**, *50*, 2593. (j) Zhou, W.; Xie, C.; Han, J.; Pan, Y. *Org. Lett.* **2012**, *14*, 4766. (k) Moon, N. G.; Harned, A. W. *Tetrahedron Lett.* **2013**, *54*, 2960.
- (4) For rare examples of carbo-cyclization, see: (a) Cahard, E.; Bremeyer, N.; Gaunt, M. J. *Angew. Chem., Int. Ed.* **2013**, *52*, 9284. (b) Yu, J.; Yang, H.; Fu, H. *Adv. Synth. Catal.* **2014**, *356*, 3669. (c) Deng, Q.-H.; Chen, J.-R.; Wei, Q.; Zhao, Q.-Q.; Lu, L.-Q.; Xiao, W.-J. *Chem. Commun.* **2015**, *51*, 3537.
- (5) (a) Gataullin, R. R.; Afon'kin, I. S.; Fatykhov, A. A.; Spirikhin, L. V.; Abdakhmanov, I. B. *Russ. Chem. Bull.* **2000**, *49*, 122. (b) Gataullin, R. R.; Afon'kin, I. S.; Fatykhov, A. A.; Abdakhmanov, I. B. *Chem. Heterocycl. Compd.* **2002**, *38*, 331. (c) Fattakhov, A. Kh.; Abdakhmanov, I. B.; Gataullin, R. R. *Russ. J. Gen. Chem.* **2008**, *78*, 1565. (d) Rauniyar, V.; Lackner, A. D.; Hamilton, G. L.; Toste, F. D. *Science* **2011**, *334*, 1681. (e) Wang, Y.-M.; Wu, J.; Hoong, C.; Rauniyar, V.; Toste, F. D. *J. Am. Chem. Soc.* **2012**, *134*, 12928.
- (6) (a) Hiyama, T. *Organofluorine Compounds: Chemistry and Applications*; Springer: Berlin, 2000. (b) Special issue on "Fluorine in the Life Sciences", *ChemBioChem* **2004**, *5*, 570. (c) Müller, K.; Faeh, C.; Diederich, F. *Science* **2007**, *317*, 1881. (d) *Fluorine in Medicinal Chemistry and Chemical Biology*; Ojima, I., Ed.; Wiley-Blackwell: Chichester, 2009.
- (7) For selected recent reviews on trifluoromethylation, see: (a) Tomashenko, O. A.; Grushin, V. V. *Chem. Rev.* **2011**, *111*, 4475. (b) Furuya, T.; Kamlet, A. S.; Ritter, T. *Nature* **2011**, *473*, 470. (c) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. *Chem. Rev.* **2011**, *111*, 455. (d) Studer, A. *Angew. Chem., Int. Ed.* **2012**, *51*, 8950. (e) Macé, Y.; Magnier, E. *Eur. J. Org. Chem.* **2012**, *2012*, 2479. (f) Liang, T.; Neumann, C. N.; Ritter, T. *Angew. Chem., Int. Ed.* **2013**, *52*, 8214. (g) Chu, L.; Qing, F.-L. *Acc. Chem. Res.* **2014**, *47*, 1513. (h) Barata-Vallejo, S.; Lantano, B.; Postigo, A. *Chem. - Eur. J.* **2014**, *20*, 16806. (i) Merino, E.; Nevado, C. *Chem. Soc. Rev.* **2014**, *43*, 6598. (j) Basset, T.; Poisson, T.; Panneccouche, X. *Chem. - Eur. J.* **2014**, *20*, 16830. (k) Egami, H.; Sodeoka, M. *Angew. Chem., Int. Ed.* **2014**, *53*, 8294. (l) Xu, J.; Liu, X.; Fu, Y. *Tetrahedron Lett.* **2014**, *55*, 585. (m) Koike, T.; Akita, M. *J. Fluorine Chem.* **2014**, *167*, 30. (n) Charpentier, J.; Friih, N.; Togni, A. *Chem. Rev.* **2015**, *115*, 650. (o) Ni, C.; Hu, M.; Hu, J. *Chem. Rev.* **2015**, *115*, 765. (p) Liu, X.; Xu, C.; Wang, M.; Liu, Q. *Chem. Rev.* **2015**, *115*, 683. (q) Alonso, C.; de Marigorta, E. M.; Rubiales, G.; Palacios, F. *Chem. Rev.* **2015**, *115*, 1847.
- (8) (a) Yoon, T. P.; Ischay, M. A.; Du, J. *Nat. Chem.* **2010**, *2*, 527. (b) Narayanan, J. M. R.; Stephenson, C. R. J. *Chem. Soc. Rev.* **2011**, *40*, 102. (c) Xuan, J.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2012**, *51*, 6828. (d) Prier, C. K.; Rankic, D. A.; MacMillan, D. W. C. *Chem. Rev.* **2013**, *113*, 5322. (e) Hari, D. P.; König, B. *Angew. Chem., Int. Ed.* **2013**, *52*, 4734. (f) Hopkinson, M. N.; Sahoo, B.; Li, J.-L.; Glorius, F. *Chem. - Eur. J.* **2014**, *20*, 3874. (g) Koike, T.; Akita, M. *Inorg. Chem. Front.* **2014**, *1*, 562.
- (9) For a review on photoredox-catalyzed trifluoromethylation, see: Koike, T.; Akita, M. *Top. Catal.* **2014**, *57*, 967.
- (10) For selected examples on photoredox-catalyzed trifluoromethylation, see: (a) Nagib, D. A.; MacMillan, D. W. C. *Nature* **2011**, *480*, 224. (b) Nguyen, J. D.; Tucker, J. W.; Konieczynska, M. D.; Stephenson, C. R. J. *J. Am. Chem. Soc.* **2011**, *133*, 4160. (c) Ye, Y.; Sanford, M. S. *J. Am. Chem. Soc.* **2012**, *134*, 9034. (d) Mizuta, S.; Verhoog, S.; Engle, K. M.; Khotavivattana, T.; O'Duill, M.; Wheelhouse, K.; Rassias, G.; Médebielle, M.; Gouverneur, V. *J. Am. Chem. Soc.* **2013**, *135*, 2505. (e) Kim, E.; Choi, S.; Kim, H.; Cho, E. *J. Chem. - Eur. J.* **2013**, *19*, 6209. (f) Wilger, D. J.; Gesmundo, N. J.; Nicewicz, D. A. *Chem. Sci.* **2013**, *4*, 3160. (g) Straathof, N. J. W.; Tegelbecker, B. J. P.; Hessel, V.; Wang, X.; Noël, T. *Chem. Sci.* **2014**, *5*, 4768. (h) Iqbal, N.; Jung, J.; Park, S.; Cho, E. *J. Angew. Chem., Int. Ed.* **2014**, *53*, 539. (i) Xu, P.; Abdukader, A.; Hu, K.; Cheng, Y.; Zhu, C. *Chem. Commun.* **2014**, *50*, 2308. (j) Carboni, A.; Dagoussset, G.; Magnier, E.; Masson, G. *Chem. Commun.* **2014**, *50*, 14197. (k) Lin, Q.-Y.; Xu, X.-H.; Qing, F.-L. *J. Org. Chem.* **2014**, *79*, 10434. (l) Carboni, A.; Dagoussset, G.; Magnier, E.; Masson, G. *Org. Lett.* **2014**, *16*, 1240. (m) Dagoussset, G.; Carboni, A.; Magnier, E.; Masson, G. *Org. Lett.* **2014**, *16*, 4340. (n) Choi, W. J.; Choi, S.; Ohkubo, K.; Fukuzumi, S.; Cho, E. J.; You, Y. *Chem. Sci.* **2015**, *6*, 1454.
- (11) For our recent reports, see: (a) Yasu, Y.; Koike, T.; Akita, M. *Angew. Chem., Int. Ed.* **2012**, *51*, 9567. (b) Yasu, Y.; Koike, T.; Akita, M. *Chem. Commun.* **2013**, *49*, 2037. (c) Yasu, Y.; Koike, T.; Akita, M. *Org. Lett.* **2013**, *15*, 2136. (d) Koike, T.; Akita, M. *Synlett* **2013**, *24*, 2492. (e) Tomita, R.; Yasu, Y.; Koike, T.; Akita, M. *Angew. Chem., Int. Ed.* **2014**, *53*, 7144. (f) Tomita, R.; Yasu, Y.; Koike, T.; Akita, M. *Beilstein J. Org. Chem.* **2014**, *10*, 1099. (g) Yasu, Y.; Arai, Y.; Tomita, R.; Koike, T.; Akita, M. *Org. Lett.* **2014**, *16*, 780.
- (12) (a) Umemoto, T.; Ishihara, S. *Tetrahedron Lett.* **1990**, *31*, 3579. (b) Umemoto, T.; Ishihara, S. *J. Am. Chem. Soc.* **1993**, *115*, 2156. (c) Umemoto, T. *Chem. Rev.* **1996**, *96*, 1757. (d) Zhang, C. *Org. Biomol. Chem.* **2014**, *12*, 6580.
- (13) Only one example of CF₃-containing spirooxazoline was reported in ref 4b, but it is a *syn*-diastereomer, which is different from the stereochemistry observed for the present reaction.
- (14) The groups of Melchiorre and Yu suggested photoinduced fluoroalkylation without a photocatalyst through a donor–acceptor complex. (a) Arceo, E.; Jurberg, I. D.; Alvarez-Fernández, A.; Melchiorre, P. *Nat. Chem.* **2013**, *5*, 750. (b) Nappi, M.; Bergonzini, G.; Melchiorre, P. *Angew. Chem., Int. Ed.* **2014**, *53*, 4921. (c) Cheng, Y.; Yuan, X.; Jiang, H.; Wang, R.; Ma, J.; Zhang, Y.; Yu, S. *Adv. Synth. Catal.* **2014**, *356*, 2859. (d) Cheng, Y.; Yuan, X.; Ma, J.; Yu, S. *Chem. - Eur. J.* **2015**, *21*, 8355.
- (15) (1R*,2S*)-3c, (1R*,2S*)-3n, and (1R*,2S*)-5b: Molecular structures are shown in the Supporting Information. CCDC 1049302, CCDC 1049303, and CCDC 1049304 contain the supplementary crystallographic data. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.